An equivalent of anti-androgen withdrawal syndrome: decrease of prostate specific antigen and clinical response to estramustine phosphate withdrawal
Levy, R.; le Maignan, C.; N'Daw, D.; Andrieu, J.M.
Presse Medicale 26(13): 611
1997
ISSN/ISBN: 0755-4982 PMID: 9180872 Document Number: 476051
Document emailed within 1 workday
Related Documents
Komiyama, T. 1997: Clinical features of alcoholics after alcohol withdrawal--withdrawal syndrome, protracted withdrawal syndrome and prolonged disturbance of alcohol dependence Nihon Rinsho. Japanese Journal of Clinical Medicine 55 Suppl: 393-405Agus, D.B.; Golde, D.W.; Sgouros, G.; Ballangrud, A.; Cordon-Cardo, C.; Scher, H.I. 1998: Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal Cancer Research 58(14): 3009-3014
Awakura, Y.; Yamamoto, M.; Fukuzawa, S.; Itoh, N.; Nonomura, M.; Fukuyama, T. 2000: Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 46(7): 449-452
Garcia-Doval, I.; LeCleach, L.; Bocquet, H.; Otero, X.L.; Roujeau, J.C. 2000: Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Archives of Dermatology 136(3): 323-327
Kelly, W.K. 1998: Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer European Urology 34(Suppl): 18-23
Narita, D.; Raica, M.; Suciu, C.; Cîmpean, A.; Anghel, A. 2006: Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer Folia Histochemica et Cytobiologica 44(3): 165-172
Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. 1991: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Research 51(1): 222-226
Edsmyr, F.; Esposti, P.L.; Andersson, L. 1980: Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate Scandinavian Journal of Urology and Nephrology. Supplementum 55: 139-142
Stromberg, J.S.; Martinez, A.A.; Horwitz, E.M.; Gustafson, G.S.; Gonzalez, J.A.; Spencer, W.F.; Brabbins, D.S.; Dmuchowski, C.F.; Hollander, J.B.; Vicini, F.A. 1997: Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment Cancer Journal from Scientific American 3(6): 346-352
Fornara, P.; Sturm, W.; Fabricius, P.G.; Schmiedt, E. 1987: Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer Der Urologe. Ausg. a 26(3): 158-161
Kelly, W.K.; Slovin, S.; Scher, H.I. 1996: Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer Seminars in Oncology 23(6 Suppl 14: 8-14
Maeda, H.; Arai, Y.; Ishitoya, S.; Okubo, K.; Aoki, Y.; Okada, T.; Maekawa, S. 1998: Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 44(5): 307-311
Sinibaldi, V.J.; Carducci, M.; Laufer, M.; Eisenberger, M. 1999: Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer Seminars in Oncology 26(5 Suppl 17: 45-48
Morgan, T.; Kofoed, L.; Petersen, D.B. 1996: Clinical pathway effects on treatment of the alcohol withdrawal syndrome South Dakota Journal of Medicine 49(6): 195-200
Wen, T.-Q.; Yang, Z.-J.; Lei, X.-L.; Xu, S.-H.; Huang, Y.; Du, G.-S.; Zhang, G.-L.; Cai, Z.; Tang, J.-P.; Cao, J.-H.; Zhang, X.-H.; Shan, F.-B. 2005: Clinical application of acupuncture for treatment of heroin withdrawal syndrome Zhongguo Zhen Jiu 25(7): 449-453
García Márquez, P.; Baz Alonso, M.J. 1993: Benzodiazepine withdrawal syndrome in newborn infants. Clinical cases Anales Espanoles de Pediatria 38(6): 555-556
Kahan, B.D.; Kerman, R.H.; Van Buren, C.T.; Flechner, S.M.; Golden, D.L.; Lewis, R.M. 1989: Clinical outcome in 36 patients after at least one and up to 5 years of steroid withdrawal based upon specific mixed lymphocyte reaction hyporesponsiveness toward the living related donor Transplantation Proceedings 21(1 Pt 2): 1579-1580
Van Poppel, H.; Werbrouck, P.W.; Baert, L. 1990: Effect of estramustine phosphate on free androgens. a comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer Acta Urologica Belgica 58(4): 89-95
Neri, B.; Bartalucci, S.; Pieri, A.; Gemelli, M.T.; Rizzo, M.; Bartoletti, R.; Trippitelli, A.; Paoletti, M.C. 1989: Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects Anticancer Research 9(1): 13-16
Da Silva, L.C.; Mattar, E.; Carrilho, F.J.; Takeda, A.; Sette Júnior, H.; Gayotto, L.C. 1983: Disappearance of hepatitis B surface antigen in chronic type B hepatitis after clinical and laboratorial relapse produced by abrupt withdrawal of immunosuppressive drugs Revista do Instituto de Medicina Tropical de Sao Paulo 25(6): 270-274